Obesity drug maker Rivus may raise over $250 million via IPO
2024-10-08 07:02:54

Asia Tech Wire (Oct 8) -- Rivus Pharmaceuticals Inc, a U.S. drug developer focused on obesity treatments, may raise more than $250 million through an IPO, according to Bloomberg.

Rivus is in talks with banks about going public and is considering a U.S. IPO as soon as this year, a report on Monday said, citing people familiar with the matter.

Rivus could aim to raise more than $250 million, one of the people familiar with the matter said.

Founded in 2019, Rivus announced in September 2022 that it had closed a $132 million Series B funding round led by RA Capital Management.

Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
ASIA TECH WIRE

Grasp technology trends

Download